RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sinopharm Group Co Stock

Sinopharm Group Co Net Income 2025

Sinopharm Group Co Net Income

8.98 B CNY

Ticker

1099.HK

ISIN

CNE100000FN7

WKN

A0N99U

In 2025, Sinopharm Group Co's profit amounted to 8.98 B CNY, a 9.16% increase from the 8.23 B CNY profit recorded in the previous year.

The Sinopharm Group Co Net Income history

YEARNET INCOME (undefined CNY)
2028e8.61
2027e8.09
2026e9.7
2025e8.98
2024e8.23
20239.05
20228.53
20217.76
20207.19
20196.25
20185.84
20175.58
20164.65
20153.77
20142.87
20132.25
20121.97
20111.56
20101.21
20090.85
20080.59
20070.38
20060.1

Sinopharm Group Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sinopharm Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sinopharm Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sinopharm Group Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sinopharm Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sinopharm Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sinopharm Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sinopharm Group Co’s growth potential.

Sinopharm Group Co Revenue, EBIT and net profit per share

DateSinopharm Group Co RevenueSinopharm Group Co EBITSinopharm Group Co Net Income
2028e714.17 B undefined28.52 B undefined8.61 B undefined
2027e695.68 B undefined29.2 B undefined8.09 B undefined
2026e690.38 B undefined23.24 B undefined9.7 B undefined
2025e648.6 B undefined21.52 B undefined8.98 B undefined
2024e610.65 B undefined19.88 B undefined8.23 B undefined
2023596.57 B undefined22.28 B undefined9.05 B undefined
2022552.15 B undefined22.54 B undefined8.53 B undefined
2021521.05 B undefined20.84 B undefined7.76 B undefined
2020456.41 B undefined19.03 B undefined7.19 B undefined
2019425.27 B undefined18.09 B undefined6.25 B undefined
2018344.53 B undefined15.75 B undefined5.84 B undefined
2017308.35 B undefined13.14 B undefined5.58 B undefined
2016258.39 B undefined10.21 B undefined4.65 B undefined
2015228.67 B undefined9.23 B undefined3.77 B undefined
2014200.13 B undefined7.86 B undefined2.87 B undefined
2013166.87 B undefined6.1 B undefined2.25 B undefined
2012135.79 B undefined4.86 B undefined1.97 B undefined
2011102.23 B undefined3.64 B undefined1.56 B undefined
201069.23 B undefined2.41 B undefined1.21 B undefined
200947.05 B undefined1.55 B undefined846 M undefined
200838.19 B undefined1.17 B undefined586 M undefined
200731.11 B undefined789 M undefined381 M undefined
200623.74 B undefined480 M undefined101 M undefined

Sinopharm Group Co stock margins

The Sinopharm Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sinopharm Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sinopharm Group Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sinopharm Group Co's sales revenue. A higher gross margin percentage indicates that the Sinopharm Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sinopharm Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sinopharm Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sinopharm Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sinopharm Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sinopharm Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sinopharm Group Co Margin History

Sinopharm Group Co Gross marginSinopharm Group Co Profit marginSinopharm Group Co EBIT marginSinopharm Group Co Profit margin
2028e8.13 %3.99 %1.21 %
2027e8.13 %4.2 %1.16 %
2026e8.13 %3.37 %1.4 %
2025e8.13 %3.32 %1.39 %
2024e8.13 %3.26 %1.35 %
20238.13 %3.73 %1.52 %
20228.59 %4.08 %1.54 %
20218.45 %4 %1.49 %
20208.83 %4.17 %1.57 %
20198.83 %4.25 %1.47 %
20189.06 %4.57 %1.69 %
20178.45 %4.26 %1.81 %
20168 %3.95 %1.8 %
20158.19 %4.04 %1.65 %
20148.16 %3.93 %1.44 %
20138.02 %3.66 %1.35 %
20128.06 %3.58 %1.45 %
20118.17 %3.56 %1.53 %
20108.43 %3.48 %1.75 %
20098.05 %3.29 %1.8 %
20087.95 %3.07 %1.53 %
20078.2 %2.54 %1.22 %
20068.38 %2.02 %0.43 %

Sinopharm Group Co Aktienanalyse

What does Sinopharm Group Co do?

Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Sinopharm Group Co's Profit Margins

The profit margins of Sinopharm Group Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Sinopharm Group Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Sinopharm Group Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Sinopharm Group Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Sinopharm Group Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Sinopharm Group Co stock

How much profit has Sinopharm Group Co made this year?

Sinopharm Group Co has made 8.98 B CNY this year.

How has the profit developed compared to last year?

The profit has increased by 9.16% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Sinopharm Group Co publish its earnings?

Sinopharm Group Co publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Sinopharm Group Co?

The profits of Sinopharm Group Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Sinopharm Group Co?

You can learn more about the earnings of Sinopharm Group Co by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Sinopharm Group Co pay?

Over the past 12 months, Sinopharm Group Co paid a dividend of 0.9 CNY . This corresponds to a dividend yield of about 4.96 %. For the coming 12 months, Sinopharm Group Co is expected to pay a dividend of 0.98 CNY.

What is the dividend yield of Sinopharm Group Co?

The current dividend yield of Sinopharm Group Co is 4.96 %.

When does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Sinopharm Group Co?

Sinopharm Group Co paid dividends every year for the past 19 years.

What is the dividend of Sinopharm Group Co?

For the upcoming 12 months, dividends amounting to 0.98 CNY are expected. This corresponds to a dividend yield of 5.38 %.

In which sector is Sinopharm Group Co located?

Sinopharm Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinopharm Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinopharm Group Co from 8/13/2024 amounting to 0.956 CNY, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Sinopharm Group Co pay the last dividend?

The last dividend was paid out on 8/13/2024.

What was the dividend of Sinopharm Group Co in the year 2024?

In the year 2024, Sinopharm Group Co distributed 0.9 CNY as dividends.

In which currency does Sinopharm Group Co pay out the dividend?

The dividends of Sinopharm Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinopharm Group Co

Our stock analysis for Sinopharm Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinopharm Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.